Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Summary

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells. However, these agents, now approved for over 15 types of cancers and for both early-stage and metastatic disease, are capable of causing inflammation in any organ system of the body that can lead to organ damage, dysfunction, and even death in rare cases.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Breast Cancer (Triple Negative Breast Cancer (TNBC))
• Renal Cell Carcinoma (Kidney Cancer)
• Melanoma (Skin Cancer)
• Non-Small Cell Lung Cancer
• MSI-H/dMMR Rectal Cancer
• Squamous Cell Carcinoma Mouth
• Invasive Mammary Carcinoma
• Classic Hodgkin Lymphoma

Eligibility basics and study details

Study type

Interventional

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Jessica Mezzanotte Sharpe

Last updated on ClinicalTrials.gov

May 6, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites